This potent topical therapy is commonly used in contexts where supportive symptomatic relief is needed for severe and challenging inflammatory skin diseases. This medicine is primarily used to address conditions marked by increased discomfort, including localized plaque psoriasis, Lichen Planus, and Discoid Lupus Erythematosus. It is applied across domains where additional symptomatic support is needed when less potent corticosteroid treatments have proven ineffective, and may assist in maintaining a sense of stability when symptoms are more noticeable in these challenging, chronic inflammatory disorders.

---

Quick Fact: Support for Distressing Symptoms

---

The medication supports the management of symptoms associated with symptoms that become more disruptive during flare-ups: severe redness, swelling, and debilitating pruritus (itching). By assisting with the management of these pronounced manifestations, the medication may assist in easing the impact of symptoms on routine activities. This treatment is also relevant for easing lesions that are dry, thickened, or scaling (hyperkeratotic). It is commonly used to help with the reduction of characteristic scaling and crusting, and contributes to easing the overall symptom load in affected areas.

Eligibility Map: Who Can and Cannot Use Dermovate Ointment — Official Regulatory Information

The eligibility profile for Dermovate Ointment (clobetasol propionate) is strictly defined by regulatory authorities to manage the risks associated with this super-high-potency topical corticosteroid.

---

Populations for Whom Use is Contraindicated

Use is contraindicated in patients with a history of hypersensitivity to the medicine or its ingredients, and in children under one year of age.

The medicine must not be used to treat specific conditions, including rosacea, acne vulgaris, perioral dermatitis, untreated cutaneous infections (viral, fungal, or bacterial), or pruritus without inflammation.

---

Age-Related and Conditional Restrictions

• Children (1–12 years): Use is not recommended by the FDA for children under 12. If used, treatment in children is generally recommended for short periods only and continuous, long-term therapy must be avoided.
• Pregnancy and Lactation: Administration should only be considered if the potential benefit to the mother outweighs the potential risk to the fetus or infant. Safe use during lactation has not been established.
• Organ Impairment: Patients with impaired liver or kidney function require restricted use; only the minimal effective amount for the shortest duration should be applied due to the risk of systemic toxicity.

The medicine is also not recommended for application to the face, groin, or axillae (underarms) or under occlusive dressings, as these areas increase the likelihood of systemic absorption.

Interactions with other medicines and products

The officially documented interaction profile for Dermovate Ointment, which contains the corticosteroid Clobetasol Propionate, is defined by effects that increase the concentration and systemic exposure of the drug in the body.

Pharmacokinetic and Exposure-Altering Interactions

The primary documented interaction is with potent inhibitors of the Cytochrome P450 3A4 enzyme (CYP3A4). Co-administration with medicines such as Ritonavir (antiviral) and Itraconazole (antifungal) is known to inhibit the metabolism of corticosteroids. This reduction in the drug's clearance leads to officially reported increased systemic exposure to Clobetasol Propionate. The resulting high plasma concentration elevates the risk of systemic effects associated with corticosteroids, such as HPA axis suppression.

Pharmacodynamic and Cumulative Exposure

Co-administration of Dermovate Ointment with other corticosteroid-containing products (either topical or systemic) may contribute to an additive effect. This additive exposure increases the total systemic corticosteroid exposure and should be considered, as noted in regulatory prescribing information.

Population-Specific Notes

This risk of increased systemic exposure from interactions is heightened in specific patient populations. Patients with liver failure or significantly impaired hepatic clearance are at an elevated risk of systemic consequences due to their reduced ability to clear the medicine from the bloodstream. No mandatory timing separation rules are explicitly documented in regulatory labels for interacting medicines.

How Dermovate Ointment Works

The action of Dermovate Ointment is driven by its active constituent, Clobetasol Propionate, which functions as an agonist for the intracellular Glucocorticoid Receptor ( GR). This binding initiates genomic reprogramming within the cell nucleus by two simultaneous actions: transrepression, which suppresses the transcription of pro-inflammatory messengers (e.g., those driven by NF-kappa B), and transactivation, which increases the expression of anti-inflammatory proteins.

This genetic modulation indirectly blocks the Arachidonic Acid Pathway by inducing the production of Annexin A1. This protein inhibits the key enzyme Phospholipase A2 ( PLA2), thus preventing the release of the precursor required to synthesize inflammatory mediators like prostaglandins and leukotrienes, supporting a more regulated state within the cellular pathways. This modulation of mediators leads directly to an increase in local vascular resistance, which stabilizes local blood flow, and engages cellular processes to inhibit the mitosis and DNA synthesis of hyperproliferative skin cells.

Administration Scope

Feature	Instruction
Route of administration	Topical (application directly onto the skin); not for oral, ophthalmic, or intravaginal use.
Dosing schedule	Apply a thin layer to the affected skin areas; the total weekly dosage must not exceed 50 grams (50 g/ week).
Timing in relation to meals (if applicable)	Not applicable, as the administration route is topical.
Preparation requirements (if applicable)	No preparation or dilution steps are required; the ointment is applied directly as supplied.
Age-group administration rules	Use is not recommended for children under 12 years of age; the ointment is contraindicated in infants under one year.
Missed-dose rules	Not specified.
Special procedural conditions	The standard treatment course is limited to 2 consecutive weeks. For localized plaque psoriasis, treatment may be extended up to 4 weeks.

---

Instruction Classifications (High-Level)

Classification	Summary
Administration method type	Topical (external, cutaneous application).
Frequency pattern	Twice daily (BID).
Standard Basis	Based on standard prescribing information.
Use-context constraints	The treated area must not be covered or wrapped with occlusive dressings unless specifically directed by a clinician.

---

Resulting Procedural Structure

Step sequence:

• Apply the ointment: A thin layer is to be applied to the affected area.
• Method: Gently and completely rub the ointment into the skin.
• Timing: Repeat the application twice per day.
• Hygiene: Wash hands thoroughly after each application (unless the hands are the area being treated).
• Duration Control: Adhere strictly to the two-week time limit for general use, with required reassessment if no improvement is seen within this period.

Connection to the overall use protocol (2–4 sentences): The established usage protocol for this preparation centers on twice-daily topical application and a 50 gram per week maximum dose. These parameters structure the administration model by controlling the frequency, duration, and method of application to the skin.

Research Evidence Overview

Clobetasol Propionate 0.05% ointment has been evaluated primarily through short-term Randomized Controlled Trials (RCTs) and systematic reviews, focusing on its role as a super-high-potency topical agent for specific, severe inflammatory skin conditions. This evidence is descriptive and remains strictly non-advisory.

---

Evidence for Core Indications

Research exploring how the ointment was evaluated in severe, localized plaque psoriasis involves short-term RCTs. The study outcomes examined included measurements related to lesion clearance and tracking changes in signs like scaling and redness over two to four weeks. Findings describe patterns observed in the studies related to the measured change in the status of the skin lesions.

For Lichen Planus, the evidence base includes meta-analyses that integrate data from various trials, focusing on outcomes related to clinical status and changes in patient-reported symptom scores such as pruritus (itching) and pain. Similarly, research for severe, unresponsive chronic eczema involves short-term, randomized, vehicle-controlled trials that measure the proportion of patients who reached a specific threshold for a study-defined outcome, such as a measured change in signs. Data show patterns related to how symptoms evolved in the observed populations during the defined, short treatment intervals.

---

Research Limitations and Uncertainty

A key limitation across all evidence is the focus on short-term outcome measures. Consequently, long-term effects are not fully established, and there is limited information regarding the recurrence rate (relapse) or the persistence of the measured change following treatment cessation. Research for pediatric subjects is less extensive than for adults, and the overall evidence quality varies across studies due to high heterogeneity and limited follow-up periods. The results apply only to the populations studied, and certainty remains low regarding the effects of long-term or chronic application.

Key Studies & References

1. Topical treatments for chronic plaque psoriasis (Cochrane Review)

Common questions about Dermovate Ointment (FAQ)

Q: Is Dermovate Ointment considered a strong or potent steroid cream?

Regulatory documents describe the active ingredient, Clobetasol Propionate 0.05%, as a super-high potency topical corticosteroid. This classification indicates that it is among the strongest types of topical steroids available. This high potency is reflected in the restricted usage protocols defined by regulatory authorities.

Q: What specific skin conditions is Dermovate Ointment officially approved to treat?

Official information indicates that the ointment is used for the relief of inflammation and itching caused by moderate to severe skin conditions that respond to corticosteroids. These approved conditions include severe plaque psoriasis and forms of chronic eczema unresponsive to certain other treatments.

Q: How quickly do people typically start noticing changes after using Dermovate Ointment?

Research and regulatory documents show that the clinical trials evaluating the ointment’s effects were typically short-term, generally lasting for two to four weeks. These time frames are used to track changes in signs and symptoms over the course of treatment, as described in official documents.

Q: Can Dermovate Ointment cause the skin to thin?

Yes, regulatory documents list skin atrophy (thinning of the skin) and striae (stretch marks) as potential local adverse effects. Regulatory documents indicate that the risk for these effects may be associated with prolonged use or use under occlusive dressings.

Q: What are the most common side effects associated with Dermovate Ointment?

The official product information notes that the most common local side effects reported at the application site include sensations like burning, stinging, irritation, itching (pruritus), and dryness. These are localized reactions to the ointment.

Q: Is it common to feel a burning or stinging sensation when first applying Dermovate Ointment?

Burning and stinging sensations at the application site are listed in regulatory documents as common local adverse reactions. It is a known reaction that can occur when applying the ointment.

Q: Is there a risk of becoming dependent on Dermovate Ointment?

Regulatory warnings indicate that abrupt discontinuation after long-term, continuous use may lead to a rebound or worsening of the original skin condition. In rare cases, abrupt cessation after long-term continuous use has been linked to potential systemic effects, such as signs of adrenal suppression.

Q: Can people with certain medical conditions, like diabetes, use Dermovate Ointment?

Regulatory documents advise that patients with certain medical conditions, such as diabetes or liver failure, may be at a higher risk of systemic side effects due to increased absorption of the medicine. Official warnings advise that use in these populations may require special caution.

Q: Is Dermovate Ointment suitable for patients who are sensitive to corticosteroids?

The official product information states that the ointment is contraindicated (should not be used) in individuals who have a known hypersensitivity or allergy to the active ingredient, Clobetasol Propionate, or any of the inactive ingredients.

Q: What is the difference between Dermovate Ointment and a regular over-the-counter cream?

Dermovate Ointment contains Clobetasol Propionate, which is classified by regulatory authorities as a super-high potency topical corticosteroid. This classification requires a prescription and differentiates it from non-prescription skin preparations.

Q: Can Dermovate Ointment be used on the face?

Regulatory warnings advise that application to the face is generally undesirable due to the increased susceptibility of facial skin to skin thinning and other localized effects. Official guidance documents emphasize that application to the face should be limited to very short periods, if used at all.

Q: Are there any areas of the body where Dermovate Ointment should not be applied?

Official warnings state the ointment should not be used on the face, groin, or axillae (armpits). These areas are generally excluded due to the risk of increased absorption or atrophy. Furthermore, it is contraindicated for ophthalmic, oral, or intravaginal use.

Q: Is Dermovate Ointment safe to use during pregnancy?

Regulatory information indicates that use during pregnancy should be avoided unless the potential benefit is deemed to justify the potential risk to the fetus, as its systemic absorption may pose a potential risk to the fetus.

Q: What are the concerns about using Dermovate Ointment while breastfeeding?

Official documents note that it is not known if topical use results in enough systemic absorption to produce detectable quantities of the medication in human milk. The ointment is not recommended for use on the breast or nipple area to avoid direct infant exposure. Caution in its use is described in official documents.

Q: Can Dermovate Ointment make my existing skin condition worse?

Regulatory documents note that its use requires caution in cases of psoriasis due to the potential for rebound relapses or the development of pustular psoriasis. The product is also contraindicated if the condition involves an existing untreated infection.

Q: What are the official warnings about stopping Dermovate Ointment suddenly?

Regulatory documents advise that therapy should be gradually discontinued once control of the condition is achieved. Official documents note that abrupt cessation has been associated with a potential relapse or rebound of the underlying dermatosis.

Q: How is Dermovate Ointment classified in terms of steroid potency?

Dermovate Ointment contains Clobetasol Propionate 0.05%, which is classified by regulatory authorities as a super-high potency topical corticosteroid. This means it is highly potent and requires restricted use under medical guidance.

Q: Can Dermovate Ointment be used for fungal infections of the skin?

Regulatory guidelines state that the ointment should not be used on untreated bacterial, fungal, or viral skin infections.

Q: Are there any dietary restrictions mentioned while using Dermovate Ointment?

Official regulatory documents and product labels do not specify any mandatory dietary restrictions associated with the topical use of Dermovate Ointment.

Q: Can Dermovate Ointment cause changes in skin color?

Yes, changes in skin color are listed in regulatory documents as potential side effects. These can include both lightening (hypopigmentation) and darkening (hyperpigmentation) of the skin where the product is applied.

Q: What is the approved use of Dermovate Ointment in older patients?

Official documents do not establish specific dosage adjustments solely based on age for geriatric patients. However, official documents note that caution may be necessary for all adults who are at risk of increased systemic absorption.

Q: Does Dermovate Ointment treat the cause of the skin condition or just the symptoms?

The mechanism of action is described in official documents as reducing the inflammatory and pruritic manifestations, which are the visible signs and symptoms of corticosteroid-responsive skin conditions. It functions by modulating inflammatory processes in the skin.

Q: Can Dermovate Ointment be used on damaged or broken skin?

Official warnings caution against applying the ointment to severely broken skin, open wounds, or ulcers. The warning is issued because application to compromised skin may significantly increase the systemic absorption of the medicine, raising the risk profile.

Q: Is Dermovate Ointment known to interact with alcohol consumption?

Official regulatory documents do not contain a specific warning or interaction listed between Dermovate Ointment (Clobetasol Propionate) and the consumption of alcohol.

Q: Why is Dermovate Ointment sometimes used in combination with other treatments?

Regulatory documents note that co-administration is advised when inflammatory lesions become infected, requiring the use of an appropriate antimicrobial or antifungal agent alongside the corticosteroid. This approach addresses both the inflammation and the concurrent condition simultaneously.

Q: Are there different strengths of Dermovate Ointment available?

The Dermovate Ointment formulation contains Clobetasol Propionate at the single strength of 0.05%, which is the standard concentration regulated by official agencies for this specific product.

Q: Can Dermovate Ointment be used for treating acne?

Regulatory contraindications explicitly state that topical corticosteroids, including Dermovate Ointment, should not be used in the treatment of acne vulgaris. This is because topical corticosteroids are not indicated for acne and may, in fact, aggravate the condition.

Q: Does Dermovate Ointment need to be kept refrigerated?

The official storage conditions state that Dermovate Ointment should be stored at room temperature, typically ranging from 15 C to 30 C (or 59 F to 86 F), and does not require refrigeration.

How to Store and Dispose of Dermovate Ointment

Official regulatory documents specify mandatory conditions for the storage and disposal of Dermovate Ointment (clobetasol propionate) to ensure product stability and safety.

Storage Requirements

Condition	Regulatory Rule
Temperature	Must be stored below 30 C; do not refrigerate or freeze.
Container	Keep in the original container and ensure the tube is tightly closed.
Child Safety	Must be kept out of the sight and reach of children.
Handling	A fire hazard warning applies: avoid smoking or naked flames near applied areas due to the flammable paraffin base.
Stability	Do not use the ointment after the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Dermovate Ointment must not be disposed of in household waste or flushed down the toilet or sink. The product must be discarded via appropriate pharmaceutical waste channels. Patients should consult a pharmacist for guidance on how to dispose of the medicine in accordance with local environmental regulations.